Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

The Intellectual Property StrategistKickerSectionsNewsLJN Newsletters

IP News

By Compiled by Kathlyn Card-Beckles
January 01, 2004

Congress Examines Ban on Patenting Human Organisms

Under a bill approved by the House of Representatives, the USPTO would be prohibited from issuing patents on human organisms. The provision would allow the USPTO to refuse to grant any application containing a claim that encompasses “any member of the species Homo sapiens at any stage of development.” The bill would codify existing USPTO rules regarding human organisms, but the ban would not interfere with stem cell research. Patents for cells, tissue and other biological products would not be affected, nor would the bill prevent patents for methods of creating biological products. Opponents of the bill argue that the provision would cripple research into therapeutic cloning and that the bill is unnecessary given the USPTO's policy on denying patents on subject matter encompassing human beings. The bill was approved in the House on Dec. 8, 2003 and awaits a vote in the Senate. See, e.g., www.bio.org.

This premium content is locked for LJN Newsletters subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

Use of Deferred Prosecution Agreements In White Collar Investigations Image

This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.

The DOJ's New Parameters for Evaluating Corporate Compliance Programs Image

The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.

CLE Shouldn't Be the Only Mandatory Training for Attorneys Image

Each stage of an attorney's career offers opportunities for a curriculum that addresses both the individual's and the firm's need to drive success.

A defendant in a patent infringement suit may, during discovery and prior to a <i>Markman</i> hearing, compel the plaintiff to produce claim charts, claim constructions, and element-by-element infringement analyses.